Xyvona (Levorphanol Tartrate Tablets) shortage — US supply status & alternatives

Xyvona (Levorphanol Tartrate Tablets)

—

In supply · Australia

Xyvona

In supply · 🇦🇺 Australia · short in🇺🇸 US

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Xyvona (Levorphanol Tartrate Tablets)
Brand names	Xyvona

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🇺🇸

United States

FDA MedWatch · 1d ago

High

Recalls official enforcement reports

🇺🇸

Xyvona (Levorphanol Tartrate Tablets)

SUN PHARMACEUTICAL INDUSTRIES INC · May 2026

Class ?details ↗

Verified timeline regulator events

🇺🇸 22 May 2026

high reported

Sources official regulators

🇺🇸

FDA MedWatch

verified 1d ago

verify ↗

Mederti Drug Report

Generated 1 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.